Financial Performance - Total revenue for Q1 2024 was $97.4 million, a 17% increase from $83.2 million in Q1 2023 on a GAAP basis[2] - Net income for Q1 2024 was $7.5 million, or $0.18 per fully diluted share, compared to a net loss of $13.5 million, or ($0.33) per fully diluted share in Q1 2023[5] - Non-GAAP adjusted EBITDA increased 60% to $17.3 million in Q1 2024, up from $10.8 million in Q1 2023[2] - Total revenues for Q1 2024 reached $97,431, a 16% increase from $83,229 in Q1 2023[20] - Net income for Q1 2024 was $7,533, compared to a net loss of $13,532 in Q1 2023[19] - Adjusted EBITDA for the same period increased to $17,312,000 from $10,805,000 year-over-year, reflecting a significant improvement[25] - Diluted income per common share improved to $0.18 from a loss of $0.33 in the same quarter last year[28] - Adjusted net income, non-GAAP, was $2,632,000 for the three months ended March 31, 2024, compared to $769,000 in the same period last year[28] Revenue Growth Drivers - Revenue growth was driven by a 26% increase in tissue processing and a 19% increase in stent grafts compared to Q1 2023[3] - Latin America region revenue grew 22% in Q1 2024 on a constant currency basis compared to the previous year[3] Future Guidance - The company raised its FY24 revenue guidance to a growth range of 9% to 12% on a constant currency basis, up from the previous range of 8% to 12%[6] - Expected revenues for FY24 are now projected to be between $386 million and $396 million, an increase from the previous range of $382 million to $396 million[6] - Non-GAAP adjusted EBITDA for FY24 is expected to increase between 26% and 34%, resulting in a range of $68 million to $72 million[6] Operational Metrics - Total current assets decreased to $276,785 from $280,668 at the end of 2023[16] - Total liabilities decreased to $489,022 from $510,617 at the end of 2023[16] - Cash and cash equivalents at the end of Q1 2024 were $51,118, down from $58,940 at the end of 2023[19] - Long-term debt increased to $313,004 from $305,531 at the end of 2023[16] - Adjusted general and administrative expenses for Q1 2024 were $48,076, compared to $45,219 in Q1 2023[24] - The company reported a decrease in cash flows used in operating activities to $(5,493) from $(6,154) year-over-year[19] - Free cash flows for the three months ended March 31, 2024, were $(9,104,000), slightly worse than $(8,997,000) in the prior year[26] Clinical and Market Developments - The On-X aortic valve clinical study showed a reduction in major bleeding risk by 87%, highlighting the clinical superiority of the aortic portfolio[3] - The company continues to focus on operational improvements and expansion into APAC and LATAM markets[11] Other Financial Details - Aortic stent grafts sales were $32,103, up 19% from $26,150 in the same period last year[22] - Preservation services revenue increased by 26% to $26,317 from $20,938 year-over-year[22] - The company reported an income before income taxes of $12,781,000 for the three months ended March 31, 2024, compared to a loss of $8,919,000 in the prior year[28] - The diluted weighted-average common shares outstanding increased to 47,886,000 from 40,432,000 year-over-year[28] - The company incurred a loss on extinguishment of debt amounting to $3,669,000 in the current quarter[28] - Business development, integration, and severance expenses resulted in an income of $(17,387,000) for the three months ended March 31, 2024[28] - Capital expenditures for the quarter were $(3,611,000), up from $(2,843,000) in the same period last year[26]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 59-2417093 (State or other jurisdiction of incorpo ...

Group 1: Stock Performance and Price Targets - Artivion (AORT) closed at $18.70, with a 6.3% gain over the past four weeks, and a mean price target of $24.44 indicating a 30.7% upside potential [1] - The average price target ranges from a low of $22 to a high of $25.75, with a standard deviation of $1.66, suggesting a relatively high agreement among analysts [1][4] - The lowest estimate indicates a 17.7% increase, while the most optimistic estimate points to a 37.7% upside [1] Group 2: Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising AORT's earnings estimates higher, which correlates with potential stock price increases [5] - The Zacks Consensus Estimate for the current year has increased by 2500%, reflecting positive sentiment among analysts [5] - AORT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [6] Group 3: Limitations of Price Targets - Price targets set by analysts can often mislead investors, as empirical research indicates they rarely predict actual stock price movements [3][4] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [3] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [4]

Artivion, Inc. (NYSE:AORT) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Laine Morgan - IR, Gilmartin Group Pat Mackin - CEO Lance Berry - CFO Conference Call Participants John McAulay - Stifel Mike Matson - Needham Suraj Kalia - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Nelson Cox - Lake Street Capital Operator Greetings, and welcome to the Artivion Fourth Quarter and Year-End 2023 Financial Conference Call. At this time, all participants are in a listen-only mode. ...

ARTIVION 3Q 2023 Earnings Presentation November 2, 2023 11 © 2023 Artivion, Inc. FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs th ...

Artivion, Inc. (NYSE:AORT) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Officer Ashley Lee - Executive Vice President and Chief Financial Officer Conference Call Participants John McAulay - Stifel Shaymus Contorno - Oppenheimer Joseph Stringer - Needham Frank Takkinen - Lake Street Capital Jeffrey Cohen - Ladenburg Thalmann Operator Welcome to the Artivion Third Quarter 2023 Financial Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware ...

Artivion, Inc. (NYSE:AORT) Q2 2023 Earnings Conference Call August 3, 2023 4:30 AM ET Company Participants Laine Morgan – Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief Financial Officer Conference Call Participants John McAulay – Stifel Shaymus Contorno – Oppenheimer Frank Takkinen – Lake Street Capital Markets Operator Greetings, and welcome to the Artivion Second Quarter 2023 Financial Conference Call. At this time, all participants are in a listen-only mode. A brief question-and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 59-2 ...

Artivion, Inc. (NYSE:AORT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President, Gilmartin Group Pat Mackin - Chief Executive Officer Ashley Lee - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Jeffrey Cohen - Ladenburg Thalmann Frank Takkinen - Lake Street Capital Operator Good day, ladies and gentlemen. And welcome to the Artivion First Quarter 2023 Financial Conference Call. All lines have been placed listen-only mode and th ...